CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on analyzing breast cancer heterogeneity using patient-derived organoids to evaluate responses to 45 FDA-approved drugs. By creating a single-cell atlas of drug sensitivities, it aims to enhance precision medicine and improve treatment outcomes for patients.
Breast cancer is the most common form of cancer in women and has a very variable prognosis.
Efficacy of anticancer therapies is limited by intertumor and intratumor heterogeneity.
To take these into account, tumor models should recapitulate native tumor heterogeneity and should be analysed at the single-cell level.
Here, we propose to take advantage of the conserved heterogeneity of breast cancer patient-derived organoids in order to analyze their response to 45 FDA-approved drugs.
These respons…
UNIVERSITAT ZURICH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
